2024 | Australia | Randomized placebo-controlled pilot trial
Narayan AJ et al. Journal of Clinical Sleep Medicine. 2024;20:753-763.
Methods: Thirty adults with primary insomnia were assigned to 150 mg of CBD nightly or placebo for two weeks after a placebo run-in. Sleep diaries, wrist actigraphy, insomnia severity, and well-being measures were collected.
Findings: CBD did not significantly outperform placebo on insomnia severity or most sleep outcomes. Some secondary measures, including well-being and objective sleep efficiency at two weeks, favored CBD.
Limitations: The short pilot trial was too small to settle effectiveness across doses or longer use. Selected positive secondary findings should not be presented as a clear overall insomnia treatment effect.